List of Excipients in Branded Drug DOPTELET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AkaRx Inc	DOPTELET	avatrombopag maleate	71369-020	CELLULOSE, MICROCRYSTALLINE	2032-07-24
AkaRx Inc	DOPTELET	avatrombopag maleate	71369-020	CROSPOVIDONE	2032-07-24
AkaRx Inc	DOPTELET	avatrombopag maleate	71369-020	FERRIC OXIDE YELLOW	2032-07-24
AkaRx Inc	DOPTELET	avatrombopag maleate	71369-020	LACTOSE MONOHYDRATE	2032-07-24
AkaRx Inc	DOPTELET	avatrombopag maleate	71369-020	MAGNESIUM STEARATE	2032-07-24
AkaRx Inc	DOPTELET	avatrombopag maleate	71369-020	POLYETHYLENE GLYCOL	2032-07-24

Doptelet Excipient Strategy and Commercial Opportunities for Avatrombopag

Last updated: August 14, 2026

Doptelet, the branded avatrombopag tablet from Swedish Orphan Biovitrum, uses a conventional immediate-release oral solid-dose platform. Its commercial opportunity is concentrated in generic tablet development, excipient supply security, differentiated lactose-free or lower-burden formulations, and global manufacturing optimization. The core formulation is technically accessible, but generic entrants must manage avatrombopag’s low dose, coating requirements, bioequivalence, patent certifications, and indication-specific regulatory exposure.

What is Doplet and how is avatrombopag formulated?

Doptelet is an oral thrombopoietin receptor agonist supplied as 20 mg tablets. The U.S. product is indicated for:

• Thrombocytopenia in adults with chronic liver disease scheduled for a procedure.
• Persistent or chronic immune thrombocytopenia in adults who have had an insufficient response to a prior treatment.[1]

The tablet contains avatrombopag maleate as the active pharmaceutical ingredient. The listed inactive ingredients include:

• Lactose monohydrate
• Microcrystalline cellulose
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Polyvinyl alcohol
• Titanium dioxide
• Talc
• Yellow ferric oxide

The formulation is a coated immediate-release tablet. The excipient system combines a soluble diluent, a compressibility aid, a superdisintegrant, a glidant, a lubricant, and film-coating components.

Component	Likely formulation role	Commercial relevance
Lactose monohydrate	Diluent and filler	Creates a potential lactose-free differentiation route
Microcrystalline cellulose	Filler and compression aid	Supports tablet hardness and blend uniformity
Croscarmellose sodium	Superdisintegrant	Critical for rapid tablet breakup
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports flow in low-dose blends
Magnesium stearate	Lubricant	Requires control of mixing time and concentration
Polyvinyl alcohol	Film-forming polymer	Supports tablet coating and appearance
Titanium dioxide	Opacifier and pigment	Used in coating color and light protection
Talc	Anti-tacking and coating aid	Supports coating-process performance
Yellow ferric oxide	Colorant	Supports product identification and market differentiation

The FDA label identifies the excipients but does not disclose quantitative levels. A developer therefore must reverse-engineer the formulation through analytical characterization, formulation screening, and comparative dissolution work rather than rely on the qualitative ingredient list alone.

What excipient strategy is most suitable for a generic Doptelet tablet?

A conventional direct-compression or dry-granulation platform is the most commercially practical starting point. Avatrombopag is administered at a low dose relative to tablet mass, so content uniformity is a central development issue.

Low-dose blend uniformity

The active ingredient must remain uniformly distributed through the powder blend. Microcrystalline cellulose and lactose can provide the bulk needed to reduce segregation risk, while colloidal silicon dioxide can improve flow. The developer should evaluate:

• Particle-size distribution of avatrombopag maleate.
• Density differences between the API and excipients.
• Blend segregation during transfer and hopper discharge.
• Assay and content uniformity across the compression run.
• Sensitivity to lubricant overmixing.

Geometric dilution, ordered blending, or dry granulation may be preferable to simple low-shear blending if the API has poor flow or a large density mismatch with the diluent system.

Disintegration and dissolution

Croscarmellose sodium is the most important disintegration component in the reference-like platform. Excessive lubricant or over-compression can slow tablet breakup and dissolution. Generic developers should optimize:

• Superdisintegrant level and distribution.
• Compression force.
• Tablet porosity.
• Magnesium stearate concentration.
• Lubrication time.
• Coating weight gain.

Avatrombopag is a small molecule with formulation-sensitive dissolution requirements. A formulation can meet immediate-release specifications while still producing a dissolution profile that differs materially from the reference product under discriminatory conditions. Comparative dissolution should cover multiple pH media and agitation conditions used in the ANDA development program.

Coating and appearance

The film coat is commercially important because the product has a low tablet strength and a defined visual identity. Polyvinyl alcohol, titanium dioxide, talc, and yellow ferric oxide create a conventional coating system. A generic manufacturer may use an alternative coating polymer or pigment system, but the change must preserve:

• Tablet identification.
• Stability.
• Moisture protection.
• Mechanical resistance.
• Dissolution performance.
• Regional color and excipient compliance requirements.

A simple film-coat substitution is unlikely to create a major technical barrier, but coating-process scale-up can create defects, weight variability, and dissolution shifts.

What commercial opportunities exist for Doptelet excipient suppliers?

The largest opportunities are in qualified excipient supply, alternate-source development, and differentiated dosage forms rather than in a novel excipient platform.

Excipient supply and dual sourcing

A generic or branded manufacturer needs reliable supply for several commodity excipients. The most commercially relevant sourcing targets are:

• Direct-compression lactose monohydrate.
• High-functionality microcrystalline cellulose.
• Pharmaceutical-grade croscarmellose sodium.
• Low-moisture colloidal silicon dioxide.
• Magnesium stearate with controlled specific surface area.
• Polyvinyl alcohol film-coating systems.
• Titanium dioxide and iron-oxide colorants.

Supplier qualification should address pharmacopoeial compliance, elemental impurities, nitrosamine risk where relevant, microbiological controls, residual solvents, particle-size consistency, and change-notification commitments.

The strongest supplier proposition is a validated, multi-site supply package with lot-to-lot performance data. A lower unit price alone is unlikely to justify a switch if the change creates dissolution, content-uniformity, or regulatory comparability work.

Functional excipient substitution

Excipient suppliers can pursue higher-value products that reduce process risk. Examples include:

• Co-processed filler-binders for direct compression.
• Low-viscosity, rapidly dispersing superdisintegrants.
• Lubricants optimized for short blending cycles.
• Ready-to-use film-coating systems.
• Low-dusting color coating concentrates.
• Excipient systems designed for low-dose uniformity.

A co-processed filler-binder could reduce the number of formulation variables, but it may also require a new bioequivalence assessment if the product’s dissolution profile changes. For a conventional ANDA, the commercial value depends on whether the excipient improves manufacturability without creating a new regulatory burden.

What lactose-free formulation opportunities exist for avatrombopag?

The reference Doptelet tablet contains lactose monohydrate. This creates a potential differentiation route, although the commercial size of the opportunity is uncertain.

A lactose-free version could replace lactose with combinations of:

• Microcrystalline cellulose.
• Mannitol.
• Dibasic calcium phosphate.
• Pregelatinized starch.
• Spray-dried alternative filler-binders.

Mannitol may improve mouthfeel and offer a recognizable lactose-free positioning, but it can alter tablet hardness, hygroscopicity, dissolution, and blend density. Dibasic calcium phosphate can improve compactibility but may create compatibility or dissolution concerns. Pregelatinized starch can support binding and disintegration but may increase moisture sensitivity.

For a generic product, lactose removal does not automatically create a market advantage. The strongest use cases are:

1. Hospital and institutional formularies with excipient-screening requirements.
2. Patients with lactose intolerance or strong excipient preferences.
3. International markets with different labeling expectations.
4. A future pediatric or smaller-dose presentation.
5. Contract-manufacturing platforms seeking one lactose-free process across multiple products.

The formulation must preserve avatrombopag exposure and tablet performance. A lactose-free claim would also require disciplined control of cross-contamination and supplier declarations.

What pediatric and alternative dosage-form opportunities exist for Doptelet?

The current commercial product is a tablet. The most plausible adjacent opportunities are smaller-dose tablets, dispersible tablets, and oral powder systems.

Smaller-dose tablets

Chronic liver disease dosing is based on baseline platelet count and can require 40 mg or 60 mg per day. ITP treatment generally uses 20 mg once daily, with dose adjustments. A 10 mg strength could reduce tablet splitting and support titration, although the commercial case depends on prescribing patterns and regulatory demand.

A 10 mg tablet would require new content-uniformity and dissolution work. It could also reduce medication waste for patients receiving lower or alternating doses.

Dispersible or multiparticulate products

A dispersible tablet, granule, or oral suspension could address swallowing difficulties and pediatric development. Such products introduce new excipient and stability questions:

• Suspending-agent compatibility.
• API sedimentation.
• Dose uniformity after reconstitution.
• Taste masking.
• Container-closure moisture protection.
• In-use stability.
• Microbial control.

Taste masking is potentially difficult because avatrombopag formulations may require coating or polymeric barriers. A multiparticulate product could provide better dose flexibility but would have a higher development and manufacturing cost than a conventional tablet.

What patents protect Doptelet and how do excipients affect generic entry?

Doptelet is protected through the standard small-molecule patent and regulatory framework rather than a biologic exclusivity structure. Generic applicants would normally pursue an abbreviated new drug application with a Paragraph III or Paragraph IV certification against listed patents in the FDA Orange Book.

The relevant legal categories are:

• Compound patents covering avatrombopag or related chemical matter.
• Composition or formulation patents.
• Method-of-use patents covering thrombocytopenia indications.
• Manufacturing or solid-form patents, if listed.
• Regulatory exclusivity associated with the original NDA or later supplements.

An excipient change does not by itself avoid an active compound patent. A generic applicant must still address every applicable Orange Book-listed patent through the required certification. A formulation patent may be more vulnerable to design-around if the generic uses a different excipient system, coating composition, manufacturing process, or dosage form.

What is the Orange Book status of Doptelet?

Doptelet is approved under NDA 210238. The current Orange Book should be used to identify active listed patents, expiration dates, pediatric exclusivity, and any approved-use information.[2] The legal assessment should distinguish:

• The remaining patent term.
• Regulatory exclusivity.
• The scope of each claim.
• Whether a patent is listed for all strengths or only a particular product.
• Whether a Paragraph IV notice has triggered patent litigation.

A formulation strategy based solely on excipient substitution is insufficient if the relevant patent claims the active compound, a broad pharmaceutical composition, or a method of treating thrombocytopenia independent of the specific excipient.

When does Doptelet lose exclusivity and what generic launch scenarios exist?

Doptelet received FDA approval in May 2018. The five-year new chemical entity exclusivity period would generally have prevented ANDA filing until four years after approval and blocked final approval until five years after approval, subject to patent litigation and applicable regulatory details.[1][3]

The principal generic launch scenarios are:

Scenario	Commercial effect
Paragraph III certification	Generic waits until the relevant patent expiration
Paragraph IV certification without litigation	Potential approval after the statutory notice and review process
Paragraph IV litigation with 30-month stay	Approval may be delayed by litigation unless the stay ends earlier
First successful Paragraph IV applicant	May obtain 180-day generic exclusivity, depending on statutory eligibility
Settlement agreement	Entry date may be earlier than patent expiration but depends on settlement terms
Formulation or use carve-out	May allow launch for non-patented indications if labeling can be legally separated

Avatrombopag is a small molecule, so biosimilar risk is not relevant. The competitive threat comes from ANDA applicants, authorized generic strategies, alternate suppliers, and potential branded lifecycle products.

Which companies are challenging Doptelet?

Public confirmation of a Paragraph IV challenger, patent lawsuit, or settlement requires review of current FDA, court, and company records. The commercially relevant challenger set includes:

• ANDA applicants developing avatrombopag tablets.
• Generic companies with thrombocytopenia portfolios.
• Contract development and manufacturing organizations supporting low-dose tablets.
• Specialty pharmaceutical companies seeking regional licensing rights.
• Manufacturers pursuing alternative strengths or dosage forms.

An ANDA applicant may remain commercially material even before litigation becomes public. Formulation development, bioequivalence trials, patent certification, and manufacturing scale-up can precede a complaint by many months.

How strong is the Doptelet patent estate?

The estate should be assessed as a layered small-molecule portfolio rather than by patent count alone.

Patent layer	Typical strength	Relevance to excipient strategy
Core compound claims	High if valid and unexpired	Cannot be avoided by changing excipients
Solid-form or salt claims	Medium to high	May require alternative API form or process
Formulation claims	Variable	Most susceptible to excipient and process design-around
Method-of-use claims	Variable	Can affect label strategy and indication carve-outs
Manufacturing claims	Variable	May affect API sourcing and process transfer

The excipient opportunity is strongest where the patent estate relies on narrow composition claims. It is weaker where patents cover broad compositions containing avatrombopag or where compound claims remain enforceable.

Patent strength should be scored against claim breadth, prosecution history, validity risk, expiration, Orange Book listing status, and the ability to produce a bioequivalent product without practicing the claim. A formulation that uses the same API, same strength, same release profile, and substantially similar excipients may face greater risk if the listed claims identify the excipient combination.

What manufacturing and IP barriers affect avatrombopag tablets?

The main manufacturing barriers are operational rather than fundamental:

• Achieving uniform distribution at a low API loading.
• Controlling tablet hardness without slowing dissolution.
• Maintaining coating uniformity across commercial-scale batches.
• Preventing segregation during transfer and packaging.
• Controlling moisture and API-excipient interactions.
• Qualifying alternate suppliers without a major regulatory change.

The main IP barriers are:

• Active compound claims.
• Listed formulation claims.
• Method-of-use claims for chronic liver disease and ITP.
• Solid-form or salt claims.
• Manufacturing-process claims.
• Trade-secret knowledge relating to blend order, compression settings, and coating parameters.

A generic developer should maintain separate design-around options for the excipient system, tablet geometry, coating polymer, and manufacturing route. That approach reduces the risk that one failed bioequivalence or patent assessment eliminates the entire program.

How does Doptelet compare with competing thrombopoietin receptor agonists?

Avatrombopag competes with eltrombopag and lusutrombopag in thrombocytopenia, while romiplostim occupies a primarily injectable position in ITP.

Product	Active ingredient	Route	Key formulation implication
Doptelet	Avatrombopag	Oral tablet	Low-dose immediate-release tablet and coating platform
Promacta/Revolade	Eltrombopag	Oral tablet or suspension in some markets	More complex interaction and administration constraints
Mulpleta/Lusutrombopag	Lusutrombopag	Oral tablet	Direct oral tablet competition in chronic liver disease
Nplate	Romiplostim	Subcutaneous injection	Injectable biologic manufacturing and cold-chain requirements

Avatrombopag has a commercial formulation advantage in that it does not carry the same prominent polyvalent-cation administration restrictions associated with eltrombopag labeling. That can support adherence and simplify institutional use.[1][4] For excipient suppliers, the opportunity is therefore less about overcoming a severe food-interaction problem and more about improving manufacturability, dose flexibility, and global supply resilience.

What revenue exposure and licensing opportunities exist?

Doptelet is a strategic commercial product for Sobi and is sold through a specialty-care model focused on hematology and liver-related thrombocytopenia. Revenue exposure is tied to:

• Periprocedural use in chronic liver disease.
• Chronic ITP treatment.
• Geographic expansion.
• Reimbursement and specialty-pharmacy access.
• Generic timing.
• Additional strengths and dosage forms.

Sobi acquired Dova Pharmaceuticals, the original commercial developer of Doptelet, in 2019. The transaction gave Sobi control of avatrombopag commercialization and related development rights.[5]

Potential licensing opportunities include:

• Regional rights in markets where Sobi has limited commercial infrastructure.
• Co-development of pediatric or flexible-dose formulations.
• Generic or authorized-generic manufacturing rights.
• Excipient and coating supply agreements tied to long-term volume.
• Technology licensing for lactose-free or dispersible formulations.
• Dual-source manufacturing arrangements for regulated markets.

The highest-value licensing target is a formulation or manufacturing package that improves access to a protected market without requiring a complete clinical development program. A commodity excipient contract is more likely to generate recurring supply revenue than high-margin IP licensing unless it includes a validated, patent-protected processing technology.

Key Takeaways

• Doptelet is a 20 mg immediate-release avatrombopag tablet using lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and conventional film-coating excipients.
• Generic formulation is technically feasible, but low-dose content uniformity and dissolution control are central development risks.
• Lactose-free tablets, 10 mg strengths, dispersible products, and pediatric-friendly dosage forms are the clearest lifecycle opportunities.
• Excipient substitution can design around narrow formulation claims but cannot avoid compound patents or broad composition claims.
• Doptelet faces generic, not biosimilar, competition.
• Dual sourcing and excipient qualification are commercially valuable because the product depends on consistent low-dose blending, compression, and coating performance.
• The current Orange Book and litigation record should control any launch-date or Paragraph IV assessment.
• Sobi’s acquisition of Dova Pharmaceuticals makes licensing, regional commercialization, and authorized-generic discussions relevant strategic avenues.

FAQs

Can a generic Doptelet product use different excipients?

Yes. An ANDA applicant can use a different excipient system if the formulation meets applicable safety, quality, bioequivalence, labeling, and regulatory requirements. The change may not avoid broad formulation or composition patent claims.

Is avatrombopag suitable for a lactose-free tablet?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, starch-based binders, or co-processed excipients. The replacement must preserve content uniformity, hardness, disintegration, dissolution, and stability.

Does Doptelet require a biosimilar development strategy?

No. Avatrombopag is a chemically synthesized small molecule. Competitive products would generally follow the generic drug pathway rather than the biosimilar pathway.

What is the most attractive new dosage form for avatrombopag?

A smaller-dose tablet is likely to have a lower technical and regulatory burden than a liquid or dispersible product. A pediatric or dysphagia-oriented formulation could have greater differentiation but would require more extensive taste, stability, dose-uniformity, and in-use testing.

Can excipient suppliers obtain patent protection around a Doptelet generic formulation?

Potentially. Patentability would depend on novelty, non-obviousness, enablement, and claim scope. A patent directed only to routine substitution of lactose or magnesium stearate would face a higher validity risk than one covering a demonstrated dissolution, stability, content-uniformity, or manufacturing improvement.

References

1. U.S. Food and Drug Administration. (2024). Doptelet (avatrombopag maleate) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Patent certifications and 180-day exclusivity.
4. U.S. Food and Drug Administration. (2023). Promacta (eltrombopag olamine) prescribing information.
5. Swedish Orphan Biovitrum AB. (2019). Sobi completes acquisition of Dova Pharmaceuticals.